Marvin L. White - 17 Jul 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
President and CEO, Director
Signature
/s/ SoYoung Kwon, Attorney-In-Fact
Issuer symbol
APVO
Transactions as of
17 Jul 2025
Net transactions value
$0
Form type
4
Filing time
21 Jul 2025, 16:36:20 UTC
Previous filing
02 May 2025
Next filing
08 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
White Marvin L President and CEO, Director 2401 4TH AVENUE, 1050, SEATTLE /s/ SoYoung Kwon, Attorney-In-Fact 21 Jul 2025 0001493324

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +10 +500% 12 17 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -10 -33% $0.000000 20 17 Jul 2025 Common Stock 30 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.